Advanced search
Start date
Betweenand


Evaluation of CIITA factor as a potential molecular adjuvant for vaccines and immunotherapies

Full text
Author(s):
Mariana de Lucena Palma
Total Authors: 1
Document type: Doctoral Thesis
Press: São Paulo.
Institution: Universidade de São Paulo (USP). Faculdade de Medicina (FM/SBD)
Defense date:
Examining board members:
Alberto Jose da Silva Duarte; Gil Benard
Advisor: Alberto Jose da Silva Duarte; Telma Miyuki Oshiro Sumida
Abstract

The CIITA factor is a protein responsible for controlling the transcription of major histocompatibility complex class II (MHC II) genes involved on antigen presentation to CD4+ T helper cells. The expression of this transcription factor is complex and differs in various cell types depending on transcriptional and post-transcriptional regulatory mechanisms. In order to investigate the CIITA factor potential as molecular adjuvant, here we developed and validated two gene delivery systems capable of promoting efficient CIITA expression in various human cell types. Additionally, we applied the delivery systems to investigate the post-translational regulation of this factor in nonimmune cells. A DNA plasmid and a lentiviral vector were produced, both carrying the human CIITA DNA sequence in silico designed to avoid cis-regulatory elements, and genetic optimized for expression efficacy in human cells. Transfection or transduction of three different non-immune human cell lines resulted in efficient CIITA expression with proper nuclear localization. The CIITA-expressing cells presented de novo MHC II molecules expression confirming the functionality of the exogenous protein, and validating both delivery systems for the future analysis of the CIITA adjuvant activity in genetic immunizations. Preliminary assays involving the inoculation of the lentiviral vector into human skin explants showed efficient transduction and expression of exogenous CIITA in primary cells. Next, monocyte-derived dendritic cells (DCs) from healthy individuals and HIV-1-infected patients were transduced with the lentiviral vector to confirm the exogenous CIITA expression in primary human cells and also evaluate the applicability of this adjuvant system to improve the DC-based vaccines against HIV. DCs from healthy and infected individuals were successfully transduced by the lentivirus, which induced a sustained CIITA mRNA production. However, the vector particles by themselves induced an unspecific upregulation of DC`s phenotypic surface markers, including the MHC II molecules, impairing our strategy to indirectly evaluate CIITA expression and activity through the detection of MHC II enhanced expression. Further investigations are necessary to confirm whether the transcription factor is efficiently expressed in transduced DCs or if these cells present a more restrict control of CIITA protein expression than the evaluated non-immune cells. Interestingly, western blot assays comparing the three human cell lines, transfected or transduced, along with inhibition of protein degradation by proteasome inhibitor treatments, allowed us to describe a new and intricate mechanism of CIITA post-translational regulation. Here we identified that each non-immune cell type maintain specific protein levels, and hence transcriptional activity, by modulating the rate of CIITA proteasomal degradation. This modulation is achieved by controlling the levels of Promyelocytic Leukemia (PML) proteins attached to Small Ubiquitin-like Modifier (SUMO) proteins, a post-translational modification required for the PML-CIITA interaction, which impairs the proteasomal degradation. This new mechanism described here contributes to the developing understanding of the CIITA post-translational regulation in non-immune cells, and might have important implications in the use of this transcription factor as a molecular adjuvant for immunotherapies (AU)

FAPESP's process: 11/12134-6 - IN VITRO CELLULAR IMMUNE RESPONSE OF HIV-1 INFECTED INDIVIDUALS INDUCED BY DENDRITIC CELLS EXPRESSING THE CIITA FACTOR AND HIV-1 GAG PROTEIN FUSED TO DC-LAMP
Grantee:Mariana de Lucena Palma
Support Opportunities: Scholarships in Brazil - Doctorate